Second- and third-line treatment of metastatic breast cancer with gemcitabine

被引：9
|
作者：
Brodowicz, T
Möslinger, R
Herscovici, V
Vaclavik, I
Wiltschke, C
Kubista, E
Zielinski, C
机构：
[1] Univ Vienna, Clin Div Oncol, A-1010 Vienna, Austria
[2] Univ Vienna, Chair Med Expt Oncol, A-1010 Vienna, Austria
[3] Univ Vienna, Dept Obstet & Gynaecol, A-1010 Vienna, Austria
[4] Univ Vienna, Dept Internal Med 1, A-1010 Vienna, Austria
来源：
EUROPEAN JOURNAL OF CANCER | 1998年 / 34卷
关键词：
D O I：
10.1016/S0959-8049(98)80169-X
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
180
引用
收藏
页码：S44 / S44
页数：1
相关论文
共 50 条
  • [21] Prediction of patients with multiple myeloma eligible for second- or third-line treatment in France
    Virginie Rondeau
    Edouard Cornet
    Philippe Moreau
    Xavier Troussard
    Annals of Hematology, 2016, 95 : 1307 - 1313
  • [22] Second- and third-line treatments in non-small cell lung cancer
    Kumar A.
    Wakelee H.
    Current Treatment Options in Oncology, 2006, 7 (1) : 37 - 49
  • [23] Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO
    I Ray-Coquard
    L Favier
    B Weber
    C Roemer-Becuwe
    P Bougnoux
    M Fabbro
    A Floquet
    F Joly
    A Plantade
    D Paraiso
    E Pujade-Lauraine
    British Journal of Cancer, 2013, 108 : 1771 - 1777
  • [24] Economic impact of second- and third-line erlotinib treatment of non small-cell lung cancer
    Chouaid, C.
    Moser, A.
    Coudray-Omnes, C.
    Vergnenegre, A.
    REVUE DES MALADIES RESPIRATOIRES, 2008, 25 (09) : 1096 - 1103
  • [25] Frequency of second- and third-line treatment among elderly Medicare stage IV colon cancer patients
    Mullins, C. Daniel
    Bikov, Kaloyan A.
    Onukwugha, Ebere
    Seal, Brian S.
    Hanna, Nader
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [26] Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO
    Ray-Coquard, I.
    Favier, L.
    Weber, B.
    Roemer-Becuwe, C.
    Bougnoux, P.
    Fabbro, M.
    Floquet, A.
    Joly, F.
    Plantade, A.
    Paraiso, D.
    Pujade-Lauraine, E.
    BRITISH JOURNAL OF CANCER, 2013, 108 (09) : 1771 - 1777
  • [27] Causes of resistance and treatment choices of second- and third-line treatment in chronic myelogenous leukemia patients
    Hochhaus, Andreas
    Ernst, Thomas
    Eigendorff, Ekkehard
    La Rosee, Paul
    ANNALS OF HEMATOLOGY, 2015, 94 : S133 - S140
  • [28] Financial toxicity from newly approved second-/third-line agents in metastatic urothelial carcinoma
    Benjamin, David J. J.
    Lythgoe, Mark P. P.
    Rezazadeh, Arash
    BJU INTERNATIONAL, 2023, 131 (06) : 691 - 693
  • [29] Amrubicin as second- or third-line treatment for women with metastatic HER2-negative breast cancer: a Sarah Cannon Research Institute phase 1/2 trial
    Yardley, Denise A.
    Raefsky, Eric
    Hainsworth, John D.
    Burris, Howard A., III
    Priego, Victor
    Inclan, Alejandro
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 148 (03) : 535 - 540
  • [30] Amrubicin as second- or third-line treatment for patients with HER2-negative metastatic breast cancer (MBC): A Sarah Cannon Research Institute phase I trial
    Barton, J. H.
    Shih, K. C.
    Raefsky, E.
    Haines, D. W.
    Strike, B.
    Hainsworth, J. D.
    Burris, H. A.
    Yardley, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345